Levodopa: a Review of Its Pharmacological Properties and Therapeutic Use with Particular Reference to Parkinsonism

Overview

Journal Drugs

Specialty Pharmacology

Date 1971 Jan 1

PMID 4340597

Citations 18

Authors

R N Brogden

T M Speight

G S Avery

Affiliations

Soon will be listed here.

Citing Articles

The expanding role of prodrugs in contemporary drug design and development.

Rautio J, Meanwell N, Di L, Hageman M Nat Rev Drug Discov. 2018; 17(8):559-587.

PMID: 29700501 DOI: 10.1038/nrd.2018.46.

Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Bryson H, Milne R, Chrisp P Pharmacoeconomics. 1992; 2(2):118-36.

PMID: 10146952 DOI: 10.2165/00019053-199202020-00005.

The short-term effect of nicotine chewing gum in patients with Parkinson's disease.

Clemens P, Baron J, Coffey D, Reeves A Psychopharmacology (Berl). 1995; 117(2):253-6.

PMID: 7753975 DOI: 10.1007/BF02245195.

Adverse effects of antiparkinsonian drugs.

Parkes J Drugs. 1981; 21(5):341-53.

PMID: 7014174 DOI: 10.2165/00003495-198121050-00002.

Sexual behavior of the male schizophrenic: the impact of illness and medications.

Nestoros J, Lehmann H, Ban T Arch Sex Behav. 1981; 10(5):421-42.

PMID: 6119066 DOI: 10.1007/BF01541435.

References

Boyd 3rd A, Lebovitz H, PFEIFFER J . Stimulation of human-growth-hormone secretion by L-dopa. N Engl J Med. 1970; 283(26):1425-9. DOI: 10.1056/NEJM197012242832602. View

Olsson R, ROOS B . Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature. 1968; 219(5153):502-3. DOI: 10.1038/219502a0. View

Proctor P . Concerning the mechanism of action of L-DOPA in Parkinsonism. Biochem Med. 1970; 4(3):357-9. DOI: 10.1016/0006-2944(70)90063-3. View

BARTHOLINI G, Pletscher A . Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol. 1969; 21(5):323-4. DOI: 10.1111/j.2042-7158.1969.tb08258.x. View

Yen H, Katz M, KROP S . Effects of various drugs on 3,4-dihydroxyphenylalanine (DL-DOPA)-induced excitation (agressive behavior) in mice. Toxicol Appl Pharmacol. 1970; 17(3):597-604. DOI: 10.1016/0041-008x(70)90034-7. View

Feldman J, Kelley W, Lebovitz H . Inhibition of glucose oxidase paper tests by reducing metabolites. Diabetes. 1970; 19(5):337-43. DOI: 10.2337/diab.19.5.337. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

POIRIER L, Sourkes T, Bouvier G, Boucher R, Carabin S . Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain. 1966; 89(1):37-52. DOI: 10.1093/brain/89.1.37. View

Dawson W . Levodopa and tests for ketonuria. N Engl J Med. 1970; 283(5):264. DOI: 10.1056/nejm197007302830516. View

10.

ERNST A . The role of biogenic amines in the extra-pyramidal system. Acta Physiol Pharmacol Neerl. 1969; 15(2):141-54. View

11.

Yahr M, Duvoisin R, HOEHN M, Schear M, BARRETT R . L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968; 93:56-63. View

12.

Coyle J, Snyder S . Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science. 1969; 166(3907):899-901. DOI: 10.1126/science.166.3907.899. View

13.

Constantinidis J, BARTHOLINI G, Tissot R, Pletscher A . Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Experientia. 1968; 24(2):130-1. DOI: 10.1007/BF02146939. View

14.

Marsh G, Markham C, ANSEL R . Levodopa's awakening effect on patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971; 34(3):209-18. PMC: 1083453. DOI: 10.1136/jnnp.34.3.209. View

15.

Butcher L, Engel J . Peripheral factors in the mediation of the effects of L-dopa on locomotor activity. J Pharm Pharmacol. 1969; 21(9):614-6. DOI: 10.1111/j.2042-7158.1969.tb08329.x. View

16.

Steele J, Richardson J, Olszewski J . PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964; 10:333-59. DOI: 10.1001/archneur.1964.00460160003001. View

17.

Bunney Jr W, Davis J . Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry. 1965; 13(6):483-94. DOI: 10.1001/archpsyc.1965.01730060001001. View

18.

Goldberg L . Levodopa and anesthesia. Anesthesiology. 1971; 34(1):1-3. View

19.

Arras M . Metabolism of D- vs L-Dopa. N Engl J Med. 1970; 282(14):813. View

20.

Cherington M . Parkinsonism, L-dopa and mental depression. J Am Geriatr Soc. 1970; 18(7):513-6. DOI: 10.1111/j.1532-5415.1970.tb02784.x. View